China's InnoVision seeks $250m for third fund
InnoVision Capital, a Chinese private equity firm founded by Lane Zhao, who was one of the original members of KKR’s China team, is targeting USD 250m for its third fund and first US dollar-denominated vehicle.
Zhao told Mergermarket, AVCJ’s sister title, that a first close of USD 90m came at the end of 2021. The hard cap has been set at USD 300m. The firm, which was established in 2016, has about CNY 16bn...
Co-Stone leads $43m round for China biosynthesis player
Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners closes debut fund on $137m
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
US regulator gets access to Chinese audits
The threat of delisting that has haunted Chinese companies that trade on US exchanges appears to have receded after the US regulators announced they had gained full access to the audits of these companies for the first time.